Disease · MONDO_0021113
Trials56
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
1 to 20 of 56
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04350593 | Dapagliflozin in Respiratory Failure in Patients With COVID-19 | Phase 3 | 1,250 | 2022-04-13 | COVID-19 | DAPAGLIFLOZIN | Its record names the disease | ClinicalTrials.gov |
| NCT04356937 | Efficacy of Tocilizumab on Patients With COVID-19 | Phase 3 | 243 | 2021-07-27 | SARS-CoV 2 | TOCILIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04311697 | Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure | Phase 2/3 | 203 | 2023-07-24 | Critical COVID-19 With Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS), Corona Virus Infection, Acute Lung Injury | AVIPTADIL | Its record names the disease | ClinicalTrials.gov |
| NCT00578734 | Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old | Phase 2 | 165 | 2012-04-27 | Acute Hypoxemic Respiratory Failure | LUCINACTANT | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT04579393 | Fostamatinib for Hospitalized Adults With COVID-19 | Phase 2 | 59 | 2022-03-02 | Coronavirus Disease 2019 | FOSTAMATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02707523 | Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children | Phase 2 | 48 | 2020-05-27 | Respiratory Syncytial Virus | AZITHROMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT04375397 | Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury | Phase 2 | 46 | 2022-06-01 | CoronaVirus Induced Disease-2019 (COVID-19) | IBRUTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04399980 | Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation | Phase 2 | 40 | 2021-05-13 | COVID 19, SARS-CoV 2, Pneumonia | MAVRILIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04388826 | COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111 | Phase 2 | 39 | 2021-11-24 | Respiratory Distress Syndrome, Adult | SABIZABULIN | Its record names the disease | ClinicalTrials.gov |
| NCT04335123 | Study of Open Label Losartan in COVID-19 | Phase 1 | 34 | 2024-08-02 | COVID-19 | LOSARTAN | Its record names the disease | ClinicalTrials.gov |
| NCT04455815 | A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) | Phase 2 | 34 | 2023-12-11 | COVID-19 Infection | CAMOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT04362111 | Early Treatment of Cytokine Storm Syndrome in Covid-19 | Phase 3 | 32 | 2023-08-24 | Cytokine Storm, COVID-19 | ANAKINRA | Its record names the disease | ClinicalTrials.gov |
| NCT01372995 | Vitamin D in Ventilated ICU Patients | Phase 2 | 31 | 2017-01-09 | Respiratory Failure | CHOLECALCIFEROL | Its record names the disease | ClinicalTrials.gov |
| NCT04372602 | Duvelisib to Combat COVID-19 | Phase 2 | 28 | 2023-03-06 | COVID-19 | DUVELISIB | Its record names the disease | ClinicalTrials.gov |
| NCT03260569 | Inhaled Nitric Oxide in Brain Injury | Phase 3 | 13 | 2025-04-30 | Traumatic Brain Injury | NITRIC OXIDE | Its record names the disease | ClinicalTrials.gov |
| NCT04463004 | Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation | Phase 2 | 2 | 2021-08-11 | COVID-19, Sars-CoV2, Pneumonia | MAVRILIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04492514 | Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation | Phase 2 | 1 | 2024-12-09 | COVID 19, SARS-CoV 2, Pneumonia | MAVRILIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT06702553 | Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass | Phase 3 | 3,650 | Nitric Oxide, Cardiac Surgery, Cardiopulmonary Bypass, Adult Patients Undergoing Cardiovascular Surgery With Cardiopulmonary Bypass | NITRIC OXIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT06468436 | Dexmedetomidine-Esketamine Combination for Sedation and Analgesia in ICU Patients | Not applicable | 1,508 | Aged, Intensive Care Units, Ventilators, Mechanical, Dexmedetomidine, Esketamine, Delirium | DEXMEDETOMIDINE, ESKETAMINE | Its record names the disease | ClinicalTrials.gov | |
| NCT03653832 | Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B Trial) | Phase 3 | 1,404 | Critical Illness | CLONIDINE, DEXMEDETOMIDINE, PROPOFOL | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0021113/trials